Compare AMRX & ICL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMRX | ICL |
|---|---|---|
| Founded | 2002 | 1968 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Agricultural Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 7.3B |
| IPO Year | 2018 | 2001 |
| Metric | AMRX | ICL |
|---|---|---|
| Price | $19.82 | $5.15 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 2 |
| Target Price | ★ $15.60 | $6.10 |
| AVG Volume (30 Days) | ★ 2.0M | 1.2M |
| Earning Date | 05-01-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 3.31% |
| EPS Growth | ★ 157.89 | N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.48 | $6.04 |
| Revenue Next Year | $7.13 | $3.27 |
| P/E Ratio | $53.53 | ★ $31.41 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.56 | $4.76 |
| 52 Week High | $21.18 | $6.97 |
| Indicator | AMRX | ICL |
|---|---|---|
| Relative Strength Index (RSI) | 64.19 | 33.65 |
| Support Level | $16.59 | $5.13 |
| Resistance Level | N/A | $5.37 |
| Average True Range (ATR) | 0.87 | 0.10 |
| MACD | 0.26 | -0.07 |
| Stochastic Oscillator | 70.42 | 5.99 |
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE. It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment, which derives maximum revenue, focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and growing solutions. These segments all contribute to the company's development of agriculture, food, and engineered material products and services. Maximum revenue is generated from its phosphate solutions segment which uses phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid (green phosphoric acid), to produce specialty products. This segment also produces and markets phosphate-based fertilizers. Geographically, the company generates revenue from Brazil, the United States of America, China, United Kingdom, Germany, Spain, Israel, France, India, Netherlands, and other countries.